Gilead to buy PepStar’s oral IL‑23R inhibitor program for roughly $1.3 billion

Gilead Sciences announced a definitive agreement to acquire PepStar Therapeutics’ oral IL‑23 receptor inhibitor program, including the Phase 1 candidate HCXT‑2001, for cash. The transaction is expected to close in the fourth quarter of 2026. Gilead said the deal will lower its GAAP and non‑GAAP earnings per share by about $0.79 to $0.83 in that quarter.

The EPS reduction reflects the cash outlay and will affect Gilead’s quarterly earnings guidance (the company expects the transaction to cut GAAP and non‑GAAP EPS by $0.79‑$0.83). The acquisition adds a differentiated oral inflammation asset to Gilead’s pipeline, expanding its options in inflammatory bowel disease and psoriasis.

  • 1Gilead will pay $1.275 billion in cash consideration, subject to customary adjustments, to acquire PepStar’s IL‑23R inhibitor program.
  • 2The deal includes worldwide rights to the investigational oral macrocyclic peptide HCXT‑2001, which is in Phase 1 clinical trials.
  • 3The transaction is expected to close in the fourth quarter of 2026.
  • 4Gilead projects the acquisition will reduce its GAAP and non‑GAAP EPS by approximately $0.79 to $0.83 in the quarter of closing.
  • 5Gilead’s chief medical officer Dietmar Berger said HCXT‑2001 could be used alone or in combination with other Gilead assets such as emvistegrast.
  • Deal value is reported as $1.275 billion in several sources (9, 6) but other outlets cite $1.28 billion (2, 7) or $1.3 billion (10, 11).

Sources